Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
IXICO plc ( (GB:IXI) ) has issued an update.
IXICO plc announced the signing of a new commercial contract for Alzheimer’s Disease imaging analysis with a leading biotechnology company and an additional project in Huntington’s Disease with an existing partner. The contracts, valued at over £0.5 million, will be recognized within a year and contribute to IXICO’s ‘Innovate, Lead, Scale’ strategy, potentially leading to further revenues. These agreements highlight IXICO’s status as a global neuroimaging market leader with a strong biomarker technology advantage.
More about IXICO plc
IXICO plc is a global leader in neuroscience imaging, utilizing an AI-driven platform to advance therapy research in neurological disorders. The company focuses on delivering insights in neuroscience to aid the development of investigational therapies for diseases such as Huntington’s, Parkinson’s, and Alzheimer’s. IXICO aims to be a leading advocate of artificial intelligence in medical image analysis, supporting pharmaceutical companies across all phases of CNS clinical research.
YTD Price Performance: -14.89%
Average Trading Volume: 39,580
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: £9.27M
For a thorough assessment of IXI stock, go to TipRanks’ Stock Analysis page.